Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?
Tuberk Toraks · 2025
DOI: 10.5578/tt.2025011058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberk Toraks, 2025. Verfasst von Elif Açar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Nasal Polyps, Rhinitis. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
Zitieren
APA
Açar, E., Köylüce, S., Şeker, S., Bozkurt Yilmaz, H. E., Aktaş Yapici, E., Arslan, B., Paçaci Çetin, G., Türk, M., & Yilmaz, İ. (2025). Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?. Tuberk Toraks. https://doi.org/10.5578/tt.2025011058
Vancouver
Açar E, Köylüce S, Şeker S, Bozkurt Yilmaz HE, Aktaş Yapici E, Arslan B, et al. Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?. Tuberk Toraks. 2025. doi:10.5578/tt.2025011058
BibTeX
@article{Aar2025,
author = {Açar, Elif and Köylüce, Serpil and Şeker, Serhat and Bozkurt Yilmaz, Hatice Eylül and Aktaş Yapici, Elif and Arslan, Bahar and Paçaci Çetin, Gülden and Türk, Murat and Yilmaz, İnsu},
title = {Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?},
journal = {Tuberk Toraks},
year = {2025},
doi = {10.5578/tt.2025011058}
}
EUVIMED